Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126047534 | 12604753 | 4 | F | 2016 | 20160808 | 20160728 | 20160812 | EXP | US-PFIZER INC-2016331876 | PFIZER | 82.00 | YR | F | Y | 64.00000 | KG | 20160812 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126047534 | 12604753 | 1 | SS | ELIQUIS | APIXABAN | 1 | 2.5 MG, 2X/DAY, ONE TABLET | AAF2694A | 0 | 2.5 | MG | FILM-COATED TABLET | BID | ||||||
| 126047534 | 12604753 | 2 | PS | TIKOSYN | DOFETILIDE | 1 | Oral | 0.25 MG, UNK | M25932 | 20931 | .25 | MG | CAPSULE, HARD | ||||||
| 126047534 | 12604753 | 3 | SS | TIKOSYN | DOFETILIDE | 1 | Oral | 250 UG, 2X/DAY | 20931 | 250 | UG | CAPSULE, HARD | BID | ||||||
| 126047534 | 12604753 | 4 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | 18 MG, 1X/DAY | 0 | 18 | MG | QD | ||||||||
| 126047534 | 12604753 | 5 | C | OXYGEN. | OXYGEN | 1 | 3 L, UNK, CONTINUOUS | 0 | 3 | L | |||||||||
| 126047534 | 12604753 | 6 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Unknown | 40 MG, UNK | 0 | 40 | MG | CAPSULE | QD | ||||||
| 126047534 | 12604753 | 7 | C | PRESERVISION | MINERALSVITAMINS | 1 | 1 DF, 1X/DAY | 0 | 1 | DF | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126047534 | 12604753 | 1 | Thrombosis prophylaxis |
| 126047534 | 12604753 | 2 | Atrial fibrillation |
| 126047534 | 12604753 | 4 | Chronic obstructive pulmonary disease |
| 126047534 | 12604753 | 5 | Chronic obstructive pulmonary disease |
| 126047534 | 12604753 | 6 | Gastrooesophageal reflux disease |
| 126047534 | 12604753 | 7 | Eye disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126047534 | 12604753 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126047534 | 12604753 | Arthralgia | |
| 126047534 | 12604753 | Arthropathy | |
| 126047534 | 12604753 | Bone pain | |
| 126047534 | 12604753 | Chronic obstructive pulmonary disease | |
| 126047534 | 12604753 | Condition aggravated | |
| 126047534 | 12604753 | Fatigue | |
| 126047534 | 12604753 | Headache | |
| 126047534 | 12604753 | Lethargy | |
| 126047534 | 12604753 | Visual acuity reduced |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126047534 | 12604753 | 1 | 201604 | 0 | ||
| 126047534 | 12604753 | 2 | 201604 | 0 | ||
| 126047534 | 12604753 | 3 | 20160328 | 0 |